Provention Bio COMPASS logo

Guiding your patients through enrollment & treatment with TZIELD

Enroll Today


Provention Bio COMPASS™

Provention Bio COMPASS™ is a personalized patient assistance and support program with helpful resources. Our team will provide information about financial assistance options, reimbursement, educational tools and resources, and additional support from the day of enrollment.
A COMPASS Navigator will be there for your patient throughout their treatment with TZIELD.
As an important resource throughout your patient’s treatment with TZIELD, the COMPASS Navigator can:
Paperwork clipboard with shield icon
Help navigate the steps to product access, including prior authorizations, medical exceptions, appeals and reauthorizations.
TZIELD infusion icon
Identify where your patient can get TZIELD infusions depending on their insurance and other factors.
Laptop information icon
Offer education on product procurement through specialty pharmacy or Buy and Bill, as well as information about reimbursement.
Online check-in icon
Perform additional check-ins with your patient once treatment is completed.
Money icon
Explain insurance coverage to your patient and provide information about financial assistance options that may be available to your patients.
Question and answer icon
Answer questions about the program and offerings.
Provention Bio COMPASS is a patient support program that helps patients gain access to TZIELD and provides patients with education and resources related to TZIELD. Provention Bio COMPASS is not a healthcare service or an insurance provider and does not provide care coordination. Provention Bio COMPASS and the COMPASS Navigator will not provide medical or treatment advice. Provention Bio COMPASS services are available only to those who have been prescribed TZIELD and are intended for US residents only.


Copay information and online enrollment

Your patients may be able to save on out-of-pocket costs for TZIELD
With the Provention Bio Copay Program,* commercially or privately insured individuals may pay as little as $0 for TZIELD. If your patient qualifies, their COMPASS Navigator can help enroll them into the copay program so they may be able to lower their out-of-pocket costs.
*Eligibility requirements and terms and conditions apply.
Click here for more information.

This program is intended to help with the cost of TZIELD and its infusion administration only. It does not help with the cost of other medicines your patients take at the same time as TZIELD or with other facility fees.
Enroll your patients online to get them started on TZIELD
The Patient START Form captures all necessary information to determine eligibility for TZIELD and initiates the enrollment process for Provention Bio COMPASS, the patient support program.
If your office prefers fax, please download a form here.
For more information about Provention Bio COMPASS, call 1-844-778-2246, Monday through Friday, 8 AM-8 PM ET.


Additional resources for download

Provention Bio COMPASS Enrollment Support

Guidance for Completing the Provention Bio COMPASS™ Patient Start Form

A detailed version of the Patient START Form that provides directions for how to successfully complete the enrollment form.


Prior Authorization (PA) Checklist

A checklist to help ensure you and your practice understand potential health plan prior authorization criteria to help prevent rejections and unnecessary delays.

Sample Letter of Medical Necessity Template

A resource that provides tips to help you draft a sample letter of necessity for your patients. A sample letter is provided for reference.

Sample Letter of Appeal Template

A resource that provides tips to help you draft a letter of appeal for your patients. A sample letter is provided for reference.

Financial Assistance

Provention Bio COMPASS™ Copay Assistance Guide

Detailed instructions on how to submit a patient copay claim and how patients can enroll in the copay program.

TZIELD Coding and Billing

Sample Coding

A quick reference sheet, including sample codes, related to coding and billing for TZIELD and its administration.

Coding and Billing Information for TZIELD® (teplizumab-mzwv)

A detailed guide with helpful information related to coding and billing for TZIELD and its administration.

Product Distribution and Ordering Information

Distribution Information for TZIELD® (teplizumab-mzwv)

A document that includes information about distribution of TZIELD and how to order it.

Considerations for TZIELD Infusions at Home

A document that has considerations for placing a supply order for TZIELD infusions at home.

Want information about TZIELD?



TZIELD is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.



  • Cytokine Release Syndrome (CRS): CRS occurred in TZIELD-treated patients during the treatment period and through 28 days after the last drug administration. Prior to TZIELD treatment, premedicate with antipyretics, antihistamines and/or antiemetics, and treat similarly if symptoms occur during treatment. If severe CRS develops, consider pausing dosing for 1 day to 2 days and administering the remaining doses to complete the full 14-day course on consecutive days; or discontinue treatment. Monitor liver enzymes during treatment. Discontinue TZIELD treatment in patients who develop elevated alanine aminotransferase or aspartate aminotransferase more than 5 times the upper limit of normal (ULN) or bilirubin more than 3 times ULN.
  • Serious Infections: Use of TZIELD is not recommended in patients with active serious infection or chronic infection other than localized skin infections. Monitor patients for signs and symptoms of infection during and after TZIELD administration. If serious infection develops, treat appropriately, and discontinue TZIELD.
  • Lymphopenia: Lymphopenia occurred in most TZIELD-treated patients. For most patients, lymphocyte levels began to recover after the fifth day of treatment and returned to pretreatment values within two weeks after treatment completion and without dose interruption. Monitor white blood cell counts during the treatment period. If prolonged severe lymphopenia develops (<500 cells per mcL lasting 1 week or longer), discontinue TZIELD.